Insmed, Inc. (NASDAQ:INSM) Stock Has Consensus Target Price of $200.30 According to Analysts

Insmed, Inc. (NASDAQ:INSM) has been assigned an average recommendation of “Moderate Buy” from the twenty-five research firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $198.91.

A number of equities analysts have issued reports on the stock. Morgan Stanley cut their price objective on shares of Insmed from $218.00 to $213.00 and set an “overweight” rating on the stock in a report on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $235.00 target price on shares of Insmed in a report on Tuesday, July 28th. Evercore reissued an “outperform” rating and set a $170.00 price target on shares of Insmed in a research report on Friday, August 7th. JPMorgan Chase & Co. dropped their price target on shares of Insmed from $179.00 to $175.00 and set an “overweight” rating on the stock in a research report on Monday, August 10th. Finally, The Goldman Sachs Group started coverage on shares of Insmed in a report on Thursday, September 24th. They set a “buy” rating and a $188.00 price target on the stock.

Insmed Trading Down 1.8%

NASDAQ:INSM opened at $93.39 on Tuesday. The company has a debt-to-equity ratio of 0.74, a current ratio of 3.72 and a quick ratio of 3.40. The firm has a 50-day moving average of $115.25 and a 200-day moving average of $115.94. The company has a market cap of $20.39 billion, a PE ratio of -22.72 and a beta of 0.83. Insmed has a one year low of $90.39 and a one year high of $212.75.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.61. The business had revenue of $425.49 million for the quarter, compared to analysts’ expectations of $395.50 million. Insmed had a negative net margin of 76.94% and a negative return on equity of 123.94%. The firm’s revenue for the quarter was up 296.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.70) EPS. As a group, equities research analysts expect that Insmed will post -1.60 EPS for the current fiscal year.

Insider Activity

In other Insmed news, COO Roger Adsett sold 239,850 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $133.27, for a total value of $31,964,809.50. Following the completion of the transaction, the chief operating officer directly owned 98,744 shares of the company’s stock, valued at $13,159,612.88. This trade represents a 70.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director David R. Brennan sold 25,000 shares of the business’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the transaction, the director owned 39,238 shares of the company’s stock, valued at $4,865,512. This trade represents a 38.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 2.10% of the stock is owned by corporate insiders.

Institutional Trading of Insmed

Several institutional investors and hedge funds have recently made changes to their positions in INSM. Reflection Asset Management purchased a new position in Insmed in the fourth quarter worth $30,000. Virginia Estate & Retirement Planning Advisors Inc. bought a new position in Insmed in the third quarter valued at $29,000. SBI Securities Co. Ltd. increased its stake in Insmed by 69.4% in the third quarter. SBI Securities Co. Ltd. now owns 349 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 143 shares during the last quarter. CX Institutional bought a new position in Insmed in the third quarter valued at $46,000. Finally, Whittier Trust Co. of Nevada Inc. raised its position in Insmed by 86.6% during the first quarter. Whittier Trust Co. of Nevada Inc. now owns 444 shares of the biopharmaceutical company’s stock valued at $73,000 after purchasing an additional 206 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. The company concentrates on conditions with significant unmet medical needs, particularly in pulmonary and infectious diseases.

Insmed’s lead commercial product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibacterial therapy used in the United States for adults with refractory Mycobacterium avium complex lung disease as part of a combination antibacterial regimen.